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Nowadays mesalamineisa commontreatmentforCrohn’sdiseaseandhypersensitivereactions tothisproducthavebeenreported.
Yetthereislimitedinformationconcerningmesalamine-inducedmyocarditisanditsmechanismisnotknown.Wedescribedacase
of mesalamine-induced myocarditis in Crohn’s disease of the colon.
1.Introduction
Mesalamine is a well-known treatment for inﬂammatory
bowel disease and drug reactions to this product are uncom-
mon. Although rare, myocarditis attributed to mesalamine
has been reported but the mechanism by which mesalamine
might prompt myocardial inﬂammation is not clearly iden-
tify. We report a case of mesalamine-induced myocarditis in
Crohn’s disease of the colon.
2.CaseReport
A 41-year-old female with Crohn’s disease on chronic
treatment with mesalamine for several years was admitted to
our hospital with severe “anginal” chest pain. The Crohn’s
disease course was well controlled with no exacerbation
for the past two years. The patient had no personal and
familial history of cardiac abnormality or dysfunction, no
hypertension or diabetes, no known allergies, and no other
home medication. There was no reported infection in the
last 6 months. Physical examination was normal and there
was no sign of cardiac failure. The chest radiograph on
admission was normal. Initial electrocardiogram showed
sinus rhythm, a ﬁrst-degree AV block, and ﬂattened T-waves
associatedwithincreasedQ-wavesintheD3lead.Laboratory
tests revealed an elevated cardiac troponin I of 6,2µg/L
(peak concentration of cardiac troponin I of 8,35µg/L), a
Creatin kinase (CK) concentration of 258U/L, a C-reactive
protein (CRP) concentration of 8mg/dL, and others blood
tests within normal parameters (including leucocytes and
eosinophils concentrations). An echocardiogram showed a
mildly dilated left atrium and limited hypokinesis of the
apical half of the left ventricle’s inferior wall. The estimated
ejection fraction was normal at 65%. Coronary angiography
was performed demonstrating normal epicardial vessels.
Cardiac magnetic resonance imaging (MRI) with delayed
enhancement showed epicardial enhancement in the apical
inferior wall and transmural enhancement in the interven-
tricular septum (Figures 1(a) and 1(b)). There was no sign
of myocardial infarction and thus, the patient was diagnosed
with acute myocarditis.
On the patient’s admission, mesalamine was discontin-
ued and two days after this withdrawal, the chest pain was
gone and cardiac troponin I (7,73µg/L) and CK decreased to
normal levels. As mesalamine has not ﬁrst been considered
as a potential agent, it was administered once more. The
reintroduction of mesalamine induced a reapparition of the
symptoms with an increased cardiac troponin I concentra-
tion(15,44µg/L)(Figure 2).Thesymptomsresolvedwithout
any treatment following a ﬁnal withdrawal of mesalamine.2 Cardiology Research and Practice
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Figure 1: Cardiac MR shows on the late enhancement sequence, transmural enhancement of the basal interventricular septum ((a) short
axis, (b) long axis).
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Figure 2: Course of systemic inﬂammation and troponin after
mesalamine re-introduction in a patient with mesalamine induced
myocarditis in Crohn’s disease of the colon.
The patient has done well since discharge. No other cardiac
MRI was performed.
3. Discussion
Cardiac diseases can be associated with Crohn’s disease
as extraintestinal manifestation of the Inﬂammatory Bowel
Disease or as a consequence of drug-induced side eﬀects.
Mesalamine-induced myocarditis is a rare but potentially
serious occurrence and several cases were described in the
literature [1–4], generally during the ﬁrst weeks of treatment
but on occasion, following treatment extending over years
[5]. Yet, the exact mechanism by which mesalamine might
prompt myocardial inﬂammation is not clearly identiﬁed.
Rarely, mesalamine can induce hypersensitive reactions such
as, hypersensitivity pneumonitis, angioedema, skin rashes,
hypereosinophilia and thus, a mechanism of hypersensitivity
to the drug rather than a direct cytotoxic eﬀect is suspected
[1–6]. The diagnosis of hypersensitivity myocarditis (HSM)
is also suggested by the fact that, in all of the cases identiﬁed
as being the result of mesalamine toxicity [1–3], there had
been a clear improvement following the discontinuation of
the drug. An eosinophilic inﬁltration of the myocardium on
endomyocardial biopsy has been described by Stelts et al. [3]
which seems to conﬁrm the link between mesalamine and
HSM.
In our case, the clinical and biological evolution was
considered as atypical for a viral myocarditis and the
diagnosis of HSM was ﬁrst evoked on the late gadolinium
enhancement in the interventricular septum. This MRI
feature has previously been described in multisystem dis-
orders with hypersensitivity reaction such as, sarcoidosis.
Moreover, this is the ﬁrst time in the literature that a case
has been described with a provocation test, carried out by
administering the potential etiologic agent once more; as
in the reports reviewed [2, 5], the severe clinical status
of the patients made this study hazardous. In our case,
this test was carried out unintentionally but it makes the
hypersensitive reaction responsible of mesalamine-induced
myocarditis indisputable. For this reason, no myocardial
biopsyhasbeentakenandnoviralserumantibodytiterswere
made but also due to the lack of oﬃcial recommendation
and the diﬃculty of viral isolation. Diﬀerent mechanisms
could explain HSM but the exact one has not yet been
identiﬁed. The most probable hypothesis seems to be an
inhibition of cyclooxygenase-1 (COX1) by the drug, which
may accelerate the metabolism of arachidonic acid toward
lipoxygenase products such as, leukotrienes [6]. This over-
production of leukotriene metabolites may induce proin-
ﬂammatory signaling, initiating the hypersensitive reaction
by liberating eosinophil-stimulating cytokines, and will lead
to the myocarditis. Further examination methods such as,
immunohistochemical or molecular biological techniques
have not been established so far.
However, this report shows that the risk of mesalamine-
induced myocarditis may be underestimated and that the
possibility of cardiac involvement needs to be considered
in patients with Inﬂammatory Bowel Disease on chronic
treatment with mesalamine and chest pain. In those cases,
themajorityofpatientsrecoverinafewdaysafterwithdrawal
of the causative agent.Cardiology Research and Practice 3
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